John Newman analyst CANACCORD

Currently out of the existing stock ratings of John Newman, 106 are a BUY (82.81%), 22 are a HOLD (17.19%).

John Newman

Work Performance Price Targets & Ratings Chart

Analyst John Newman works at CANACCORD with a stock forecast success ratio of 32.63% fulfilled within 98.04 days on average.

John Newman’s has documented 237 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ACLX, Arcellx at 29-Feb-2024.

Wall Street Analyst John Newman

Analyst best performing recommendations are on TSVT (2SEVENTY BIO).
The best stock recommendation documented was for ACLX (ARCELLX) at 4/19/2023. The price target of $40 was fulfilled within 5 days with a profit of $4.74 (13.44%) receiving and performance score of 26.89.

Average potential price target upside

AGIO Agios Pharm ATRA Atara Biotherapeutics IMGN ImmunoGen MCRB Seres Therapeutics OCUP Ocuphire Pharma REGN Regeneron Pharmaceuticals SESN Sesen Bio BLUE Bluebird bio RDUS Schnitzer Steel Industries ALDX Aldeyra The ARAV Aravive CELG Celgene GBT Global Blood Therapeutics SELB Selecta Biosciences SGYP Synergy Pharmaceuticals ACET Adicet Bio HSTO Histogen SAGE Sage Therapeutic ACLX Arcellx ALLO Allogene Therapeutics BCEL Atreca ONCY Oncolytics Biotech TSVT 2Seventy Bio

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

30

$2.3 (8.30%)

32

1 months 27 days ago

3/3 (100%)

$-2.99 (-9.06%)

224

Hold

28

$0.3 (1.08%)

32

5 months 16 days ago

6/6 (100%)

$5.51 (24.50%)

192

Buy

42

$14.3 (51.62%)

67

9 months 23 days ago

5/12 (41.67%)

$13.87 (49.31%)

213

Buy

38

$10.3 (37.18%)

40

9 months 23 days ago

0/4 (0%)

$9.87 (35.09%)

Buy

37

$9.3 (33.57%)

33

1 years 8 months 14 days ago

6/11 (54.55%)

$7.26 (24.41%)

69

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is John Newman is most bullish on?

Potential upside of $127.52 has been obtained for REGN (REGENERON PHARMACEUTICALS)

Which stock is John Newman is most reserved on?

Potential downside of -$0 has been obtained for IMGN (IMMUNOGEN)

What Year was the first public recommendation made by John Newman?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?